{"id":"W4406486966","doi":"10.1080/14796694.2024.2440277","title":"Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; University of Alberta; Precision Nanosystems (Canada); University of Ottawa; University of British Columbia; Ottawa Hospital; Queen's University","funders":"National Health and Medical Research Council; Medical Research Council; Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Bristol-Myers Squibb","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Internal medicine; Hormone therapy; Cancer; Androgen receptor; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004301629,0.0002186628,0.0007169568,0.0001350263,0.0001504319,0.00001035173,0.0001360047,0.0001261371,0.00003350707],"category_scores_gemma":[0.00008811667,0.000111662,0.0001656437,0.0004071782,0.0002639523,0.0000410531,0.00005085265,0.0003035658,8.006338e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005606968,"about_ca_system_score_gemma":0.001839762,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001761331,"about_ca_topic_score_gemma":0.0009367989,"domain_scores_codex":[0.9985279,0.0001836354,0.0003104684,0.0003215452,0.0002793532,0.0003770423],"domain_scores_gemma":[0.9986671,0.0004717112,0.0001785271,0.0003276736,0.0002773974,0.00007757041],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.8431498,0.0009150205,0.001374621,0.0004648727,0.002471814,0.0002485987,0.009087046,0.00003124317,0.007917685,0.0005379612,0.03675686,0.09704452],"study_design_scores_gemma":[0.3695102,0.03360495,0.003980244,0.0006320326,0.001280429,0.00004565581,0.008639638,0.0001225853,0.07777204,0.0005653627,0.5034718,0.0003750861],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.944756,0.01777219,0.0002099725,0.02601883,0.0007732327,0.007498829,0.001224537,0.00004777697,0.001698649],"genre_scores_gemma":[0.9411916,0.01568977,0.00457026,0.004616492,0.001946875,0.004192496,0.0005144339,0.0001239539,0.02715409],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4736396,"threshold_uncertainty_score":0.4553443,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01844197879047274,"score_gpt":0.3590594813406267,"score_spread":0.3406175025501539,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}